Recalling the Pathology of Parkinson’s disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to step‐up

2021 ◽  
Author(s):  
Arif Mahmood ◽  
Abid Ali Shah ◽  
Muhammad Umair ◽  
Yiming Wu ◽  
Amjad Khan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Genetic Evidence ◽  
Exact Figure

scholarly journals Finding drug targeting mechanisms with genetic evidence for Parkinson’s disease

2020 ◽  
Author(s):  
Catherine S. Storm ◽  
Demis A. Kia ◽  
Mona Almramhi ◽  
Sara Bandres-Ciga ◽  
Chris Finan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Targeting ◽  
Drug Targets ◽  
Molecular Mechanisms ◽  
Disease Risk ◽  
Target Identification ◽  
Causal Effect ◽  
Age At Onset ◽  
Genetic Evidence

SummaryParkinson’s disease (PD) is a neurodegenerative movement disorder that currently has no disease-modifying treatment, partly owing to inefficiencies in drug target identification and validation using human evidence. Here, we use Mendelian randomization to investigate more than 3000 genes that encode druggable proteins, seeking to predict their efficacy as drug targets for PD. We use expression and protein quantitative trait loci for druggable genes to mimic exposure to medications, and we examine the causal effect on PD risk (in two large case-control cohorts), PD age at onset and progression. We propose 23 potential drug targeting mechanisms for PD, of which four are repurposing opportunities of already-licensed or clinical-phase drugs. We identify two drugs which may increase PD risk. Importantly, there is remarkably little overlap between our MR-supported drug targeting mechanisms to prevent PD and those that reduce PD progression, suggesting that molecular mechanisms driving disease risk and progression differ. Drugs with genetic support are considerably more likely to be successful in clinical trials, and we provide compelling genetic evidence and an analysis pipeline that can be used to prioritise drug development efforts for PD.

scholarly journals No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease

2020 ◽  
Vol 87 ◽  
pp. 140.e19-140.e22 ◽  
Author(s):  
Jonggeol Jeffrey Kim ◽  
Sara Bandres-Ciga ◽  
Cornelis Blauwendraat ◽  
Ziv Gan-Or
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Alcohol Dehydrogenase ◽  
Genetic Evidence

Evaluation of Efferent Auditory System and Hearing Quality in Parkinson's Disease: Is the Difficulty in Speech Understanding in Complex Listening Conditions Related to Neural Degeneration or Aging?

2020 ◽  
pp. 1-9
Author(s):  
Nuriye Yıldırım Gökay ◽  
Bülent Gündüz ◽  
Fatih Söke ◽  
Recep Karamert
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Auditory System ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Auditory Pathway ◽  
Normal Hearing ◽  
System Function ◽  
Distortion Product

Purpose The effects of neurological diseases on the auditory system have been a notable issue for investigators because the auditory pathway is closely associated with neural systems. The purposes of this study are to evaluate the efferent auditory system function and hearing quality in Parkinson's disease (PD) and to compare the findings with age-matched individuals without PD to present a perspective on aging. Method The study included 35 individuals with PD (mean age of 48.50 ± 8.00 years) and 35 normal-hearing peers (mean age of 49 ± 10 years). The following tests were administered for all participants: the first section of the Speech, Spatial and Qualities of Hearing Scale; pure-tone audiometry, speech audiometry, tympanometry, and acoustic reflexes; and distortion product otoacoustic emissions (DPOAEs) and contralateral suppression of DPOAEs. SPSS Version 25 was used for statistical analyses, and values of p < .05 were considered statistically significant. Results There were no statistically significant differences in the pure-tone audiometry thresholds and DPOAE responses between the individuals with PD and their normal-hearing peers ( p = .732). However, statistically significant differences were found between the groups in suppression levels of DPOAEs and hearing quality ( p < .05). In addition, a statistically significant and positive correlation was found between the amount of suppression at some frequencies and the Speech, Spatial and Qualities of Hearing Scale scores. Conclusions This study indicates that medial olivocochlear efferent system function and the hearing quality of individuals with PD were affected adversely due to the results of PD pathophysiology on the hearing system. For optimal intervention and follow-up, tasks related to hearing quality in daily life can also be added to therapies for PD.

Recent Medical and Surgical Treatments for Parkinson's Disease

1999 ◽  
Vol 4 (1) ◽  
pp. 9-12
Author(s):  
Philip M. Green
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Surgical Treatments

Accessible Internet Training for People With Aphasia and Parkinson's Disease

2004 ◽  
Vol 9 (2) ◽  
pp. 10-13
Author(s):  
Linda Worrall ◽  
Jennifer Egan ◽  
Dorothea Oxenham ◽  
Felicity Stewart
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease

Voice Treatment for Individuals With Parkinson's Disease

2007 ◽  
Vol 12 (1) ◽  
pp. 2-11
Author(s):  
Lorraine Ramig ◽  
Cynthia Fox
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Voice Treatment
Sign in / Sign up

Export Citation Format

Share Document